AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21215151
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (group A)
Trial: 16780265
Drug: Betahistine treatment
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine treatment
Trial: 16780265
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (different drugs)
Trial: 15496643
Drug: desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: desloratadine 5 mg plus fluoxetine 20 mg
Trial: 15496643
Drug: fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluoxetine 20 mg plus desloratadine 5 mg
Trial: 9438485
Drug: QID dosing
RxNorm normalized name: MINOXIDIL 5 g in 100 mL / BIOTIN 5 g in 100 mL EXTRACORPOREAL AEROSOL, FOAM [QIDILA 5% Minoxidil Foam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QID dosing of inhaled corticosteroids
Trial: 9438485
Drug: 8 AM
RxNorm normalized name: ACETYL HEXAPEPTIDE-8 AMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 AM dosing of inhaled corticosteroids
Trial: 8102538
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (n = 9)
Trial: 23867808
Drug: QVA149 (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 (110 μg indacaterol/50 μg glycopyrronium)
Trial: 24159259
Drug: IND+GLY (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND+GLY (150 μg indacaterol and 50 μg glycopyrronium)
Trial: 16510466
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg t.i.d.)
Trial: 15107368
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (active mobilisation)
Trial: 15107368
Drug: Collar therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collar therapy (cervical orthosis)
Trial: 9735623
Drug: Mechanical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical treatment with taping and orthoses
Trial: 7986837
Drug: Spiral CT
RxNorm normalized name: Trichinella spiralis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiral CT technique, CM dosage of 50 ml (30 ml at a flow rate of 2 ml/s and 20 ml at 0.7 ml/s)
Trial: 31305423
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no CPAP therapy)
Trial: 21355003
Drug: Trastuzumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab monotherapy
Trial: 16530506
Drug: Biofeedback (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback (5 weekly sessions)
Trial: 16530506
Drug: Laxatives (polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxatives (polyethylene glycol 14.6‐29.2 g/day plus 5 weekly counseling sessions)
Trial: 10657405
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antithrombotic treatment)
Trial: 9301505
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (25 g/day)
Trial: 9301505
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran (64 g/day)
Trial: 9301505
Drug: Processed wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Processed wheat bran (Kellogg's All Bran, 38 g/day)
Trial: 3548611
Drug: Imipenem (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (500 mg t.i.d.)
Trial: 3548611
Drug: Netilmicin plus
RxNorm normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netilmicin plus Clindamycin (600 mg t.i.d.)
Trial: 24178405
Drug: Rotational conjunctival
RxNorm normalized name: Sus scrofa conjunctiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotational conjunctival flap with adjunctive subconjunctival 2.5 mg/0.1 ml bevacizumab injection (Group C)
Trial: 20862715
Drug: Intravenous anisodamine
RxNorm normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anisodamine after surgery for 3 days
Trial: 1814603
Drug: Ranitidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine infusion at 6.25 mg/hr
Trial: 1814603
Drug: Ranitidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine infusion at 10.0 mg/hr
Trial: 1814603
Drug: Ranitidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine infusion (6.25 mg/hr and 10.0 mg/hr)
Trial: 1814603
Drug: Ranitidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine infusion
Trial: 16135590
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment (single intramuscular injection of cefoxitin and oral doxycycline)
Trial: 16135590
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment (intravenous cefoxitin and doxycycline)
Trial: 9346384
Drug: EPO treatment
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO treatment (group II, n = 42)
Trial: 1443808
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg.kg‐1 bolus, continuous infusion of 5 mg.kg‐1.h‐1) and alfentanil (10 micrograms.kg‐1 bolus, 5 micrograms.kg‐1 infusion)
Trial: 1443808
Drug: Etomidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.3 mg.kg‐1 bolus, continuous infusion of 1.5 mg.kg‐1.h‐1) and alfentanil (10 micrograms.kg‐1 bolus, 5 micrograms.kg‐1 infusion)
Trial: 9751091
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin
Trial: 22515588
Drug: Targeted narrowband
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted narrowband UVB phototherapy with psoralen gel (Group 2)
Trial: 12676890
Drug: d-Amphetamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine (0, 2.5, 5, 10, and 15 mg)
Trial: 1499947
Drug: Phentolamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (5 mg/2 min followed by 500 micrograms/min)
Trial: 1499947
Drug: Propranolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (5 mg/2 min followed by 80 micrograms/min)
Trial: 25025852
Drug: Ghavoot (34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghavoot (34 g/dl) dissolved in 400 ml milk
Trial: 25025852
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 400 ml milk
Trial: 22075751
Drug: fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 160 mg/d for 3 weeks
Trial: 12897561
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia with propofol 5 to 8 mg.kg‐1.h‐1 and remifentanil 10 to 30 microg.kg‐1.h‐1
Trial: 12897561
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia with propofol-remifentanil
Trial: 10581665
Drug: Emergency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency treatment for acute exacerbations of obstructive pulmonary disease
Trial: 22233697
Drug: Risperidone oral
RxNorm normalized name: risperidone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone oral solution (RIS-OS) plus clonazepam
Trial: 22233697
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (RIS-OS plus clonazepam)
Trial: 22233697
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments after 6-week treatment
Trial: 14613759
Drug: Naringin (400mg/capsule/day)
RxNorm normalized name: Naringin
DrugBank: Naringin (DB16859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naringin (400mg/capsule/day) for 8 weeks
Trial: 31793231
Drug: Intravenous rezafungin
RxNorm normalized name: Rezafungin
DrugBank: Rezafungin (DB16310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rezafungin (600 mg and 1400 mg)
Trial: 30616912
Drug: Nemonoxacin 500
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 500 mg (NEMO-500MG)
Trial: 30616912
Drug: Nemonoxacin 750
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 750 mg (NEMO-750MG)
Trial: 30616912
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg (LEVO)
Trial: 21329501
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation therapy (CST) delivered to participants with mild AD and their companions together.
Trial: 21329501
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation therapy (CST) delivered to companions of participants with mild AD alone.
Trial: 21329501
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation therapy (CST) for participants with mild AD and their companions together.
Trial: 21329501
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation therapy (CST) for companions of participants with mild AD alone.
Trial: 20110015
Drug: Generic chlorphenesin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic chlorphenesin carbamate 250 mg
Trial: 20110015
Drug: Generic chlorphenesin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic chlorphenesin carbamate 500 mg
Trial: 20110015
Drug: Branded chlorphenesin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded chlorphenesin carbamate 250 mg
Trial: 20110015
Drug: Branded chlorphenesin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded chlorphenesin carbamate 500 mg
Trial: 15385380
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block with lidocaine 1.5% 15 mL (group FEM)
Trial: 11118395
Drug: Intramuscular route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular route
Trial: 17764789
Drug: Subcutaneous route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous route
Trial: 9701523
Drug: Omeprazole therapy
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole therapy (duration: 80 months for hypergastrinaemia group, 55 months for control group)
Trial: 8254816
Drug: RDA multivitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDA multivitamins plus 40,000 units vitamin A, 100 mg. vitamin B6, 2,000 mg. vitamin C, 400 units vitamin E and 90 mg. zinc
Trial: 2572666
Drug: xamoterol 200
RxNorm normalized name: xamoterol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol 200 mg b.i.d. for 4 weeks
Trial: 1058527
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days pretreatment with 1‐asparaginase and prednisolone followed by a combination of rubidomycin and cytosine arabinoside (ARAP)
Trial: 1058527
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a combination of rubidomycin, cytosine arabinoside and prednisolone without 1‐asparaginase pretreatment (RAP)
Trial: 8513841
Drug: Hydrocortisone 1%
RxNorm normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1% cream
Trial: 23352226
Drug: FF/VI 50/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 50/25 μg
Trial: 23332861
Drug: FF/VI 200/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 200/25 μg
Trial: 26059225
Drug: FF/VI 50/25-200/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 50/25-200/25 μg
Trial: 18452345
Drug: Quetiapine 300
RxNorm normalized name: quetiapine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 300 mg/day
Trial: 18452345
Drug: Quetiapine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 600 mg/day
Trial: 16702815
Drug: 9-aminocamptothecin (9-AC)
RxNorm normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-aminocamptothecin (9-AC) with CD formulation, 9.44 to 12.60 mg/m/cycle for 14 days
Trial: 12620439
Drug: Transdermal E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal E(2) patch
Trial: 12620439
Drug: Transdermal E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal E(2) gel
Trial: 11762805
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (ciprofloxacin 750 mg plus roxithromycin 150 mg, bid. days 4-13)
Trial: 9048239
Drug: Norethindrone acetate
RxNorm normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethindrone acetate (10 mg) with leuprolide acetate (1 mg)
Trial: 9048239
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (1 mg) alone
Trial: 29605753
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group 2 - midwifery intervention plus dental intervention involving assessment/treatment from cost free local dental services
Trial: 29605753
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - received oral health information at recruitment
Trial: 25239521
Drug: nab-paclitaxel (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (135 mg/m2, d1, 8, q3w) plus carboplatin (AUC 5, d1, q3w)
Trial: 25239521
Drug: gemcitabine (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine (1,250 mg/m2, d1, 8, q3w) plus carboplatin (AUC 5, d1, q3w)
Trial: 22246377
Drug: Exenatide (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (0.12 pmol/kg/min) infusion for 6 hours
Trial: 22246377
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 6 hours
Trial: 571216
Drug: 25% salt‐poor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% salt‐poor human albumin (1.5 ml/kg)
Trial: 571216
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl in water (normal saline) (7 ml/kg)
Trial: 26051574
Drug: Prolotherapy (hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy (hypertonic dextrose injection)
Trial: 21034693
Drug: citalopram +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: citalopram + pindolol (5 mg tid)
Trial: 17416939
Drug: Timolol/dorzolamide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol/dorzolamide combination therapy
Trial: 14657813
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 16 to 32 mg/kg/d for 6 days
Trial: 10609908
Drug: Nitroglycerin 1
RxNorm normalized name: nitroglycerin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin 1 mg/ml
Trial: 2014087
Drug: Short-term cefoxitin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term cefoxitin prophylaxis (3 doses)
Trial: 2014087
Drug: Long-term cefoxitin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term cefoxitin prophylaxis (12 doses)
Trial: 7049077
Drug: Clofazimine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine (200 mg daily for 5 days)
Trial: 31116261
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day adjunctive minocycline for MDD
Trial: 23154591
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional therapy without ARB (control group)
Trial: 21252014
Drug: BIOBYPASS (AdGVVEGF121.10NH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIOBYPASS (AdGVVEGF121.10NH) gene therapy
Trial: 3933035
Drug: Fluphenazine enanthate
RxNorm normalized name: Fluphenazine Enanthate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine enanthate (25 mg)
Trial: 3933035
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate (25 mg)
Trial: 26426458
Drug: Apneic oxygenation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apneic oxygenation (15 L/min of 100% oxygen via high-flow nasal cannula during laryngoscopy)
Trial: 21406601
Drug: lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 10 to 20 mg/d
Trial: 21406601
Drug: lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 10 to 20 mg/d plus simvastatin 20 mg/d
Trial: 12074203
Drug: Quinine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 400 mg per day
Trial: 7488449
Drug: Vasodilator drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilator drug treatment for 12 weeks
Trial: 21848526
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of glutamate
Trial: 21848526
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (isotonic saline injection)
Trial: 9879698
Drug: IgM antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM antibodies reacting with the terminal disaccharide of galactose (beta1‐3)N‐acetylgalactosamine
Trial: 23930866
Drug: Ketamine 1
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1 mg/kg
Trial: 2700773
Drug: 1‐mg dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐mg dexamethasone suppression test (DST)
Trial: 24561125
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg once daily
Trial: 23278906
Drug: Group H:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group H: 1 ml·kg(‐1) of 0.25% ropivacaine injected after needle pierced the sacrococcygeal ligament under ultrasound guidance
Trial: 9290118
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation at 30 mg/day
Trial: 3602015
Drug: Atenolol/diuretic (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol/diuretic (5 mg amiloride plus 50 mg hydrochlorothiazide once daily)
Trial: 3602015
Drug: Atenolol/nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol/nifedipine (20 mg nifedipine twice daily)
Trial: 12392115
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal daily activities)
Trial: 31150502
Drug: Antidepressants and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants and Oxytocin
Trial: 23601522
Drug: Routine medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medicine treatment (Group 2)
Trial: 23601522
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Non-intervention group)
Trial: 10349922
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 0.5%
Trial: 10349922
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 1%
Trial: 10349922
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 2%
Trial: 10349922
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml normal saline at sevoflurane 0.5%
Trial: 10349922
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. (all concentrations)
Trial: 10349922
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml normal saline (all concentrations)